Lipocine Inc LPCN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
-
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
-
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
-
Lipocine Appoints Michael J. Grissinger to Board of Directors
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.72–1.90
- 52-Week Range
- $1.72–12.37
- Bid/Ask
- $1.75 / $1.76
- Shares Outstanding
- 8.24M
- Market Cap
- $14.18M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.lipocine.com
Valuation
|
Metric
|
LPCN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.65 |
Price/Sales | 7.44 |
Price/Cash Flow | — |
Price/Earnings
LPCN
Financial Strength
|
Metric
|
LPCN
|
|---|---|
Quick Ratio | 11.39 |
Current Ratio | 11.48 |
Interest Coverage | — |
Quick Ratio
LPCN
Profitability
|
Metric
|
LPCN
|
|---|---|
Return on Assets (Normalized) | −57.86% |
Return on Equity (Normalized) | −64.58% |
Return on Invested Capital (Normalized) | −67.72% |
Return on Assets
LPCN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|ffLVwr% | LOCK|%$Wmh | $129B | |||
| Moderna Inc
MRNA
| LOCK|CN#Wq!> | LOCK|D@l | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|X!&kzL | LOCK|q!N< | $77B | |||
| argenx SE ADR
ARGX
| LOCK|?c^k#j | LOCK|xb | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|SdJgnMD | LOCK|p? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y@yWTd | LOCK|q#b@N | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$bVQTfT& | LOCK|@^Qv | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$vQt#^ | LOCK|Zs& | $24B | |||
| Incyte Corp
INCY
| LOCK|h&<rNnL | LOCK|P% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|cTsS<p | LOCK|$! | $14B |
United States